cynk-001
Cell therapyexperimentalCOVID-19
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 12, 2020 (NCT04310592)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Alkylating Agents · Phase 1
- Analgesics · Phase 1/Phase 2
- Analgesics, Non-Narcotic · Phase 1/Phase 2
- Anti-Infective Agents · Phase 1/Phase 2
- Antimetabolites, Antineoplastic · Phase 1/Phase 2
- Antineoplastic Agents · Phase 1/Phase 2
- Antiviral Agents · Phase 1/Phase 2
- Blood Protein Disorders · Phase 1/Phase 2
- Cardiovascular Diseases · Phase 1/Phase 2
- Coronaviridae Infections · Phase 1/Phase 2
- Coronavirus · Phase 1/Phase 2
- Coronavirus Infections · Phase 1/Phase 2
- Cyclophosphamide · Phase 1
- Glioblastoma · Phase 1/Phase 2
- Hematologic Diseases · Phase 1/Phase 2
- Hematologic Neoplasms · Phase 1
- Hemorrhagic Disorders · Phase 1/Phase 2
- Hemostatic Disorders · Phase 1/Phase 2
- Immune System Diseases · Phase 1/Phase 2
- Immunologic Factors · Phase 1/Phase 2
- Immunoproliferative Disorders · Phase 1/Phase 2
- Immunosuppressive Agents · Phase 1
- Leukemia · Phase 1
- Leukemia, Myeloid · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lung Diseases · Phase 1/Phase 2
- Lymphoproliferative Disorders · Phase 1/Phase 2
- Molecular Mechanisms of Pharmacological Action · Phase 1
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Neoplasms by Histologic Type · Phase 1/Phase 2
- Neoplasms, Plasma Cell · Phase 1/Phase 2
- Nidovirales Infections · Phase 1/Phase 2
- Paraproteinemias · Phase 1/Phase 2
- Peripheral Nervous System Agents · Phase 1/Phase 2
- Physiological Effects of Drugs · Phase 1/Phase 2
- Pneumonia · Phase 1/Phase 2
- Pneumonia, Viral · Phase 1/Phase 2
- Respiratory Tract Diseases · Phase 1/Phase 2
- Respiratory Tract Infections · Phase 1/Phase 2
- RNA Virus Infections · Phase 1/Phase 2
- SARS-CoV-2 · Phase 1/Phase 2
- Sensory System Agents · Phase 1/Phase 2
- Severe Acute Respiratory Syndrome · Phase 1/Phase 2
- Vascular Diseases · Phase 1/Phase 2
- Virus Diseases · Phase 1/Phase 2
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05218408 | Phase 1/Phase 2 (Phase 2) | Mar 8, 2022 | Celularity, Inc. |
| NCT04489420 | Phase 1 | Oct 1, 2020 | Celularity, Inc. |
| NCT04365101 | Phase 1/Phase 2 (Phase 2) | May 13, 2020 | Celularity, Inc., Immune Design, Lung Biotechnology PBC |
| NCT04309084 | Phase 1/Phase 2 (Phase 2) | Mar 12, 2020 | Celularity, Inc. |
| NCT04310592 | Phase 1 | Mar 12, 2020 | Celularity, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celularity, Inc. | For profit | 5 | 5 | 2 | 2020 |
| Immune Design | For profit | 1 | 0 | 1 | 2020 |
| Lung Biotechnology PBC | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1